Platelet Reactivity in Acute Non-disabling Cerebrovascular Events "PRINCE"

Active, not recruiting

Phase 2/3 Results N/A

Summary of Purpose

Ticagrelor is a reversible and direct-acting oral antagonist of the P2Y12 (Purinergic receptor P2Y, G-protein coupled, 12) receptor for adenosine diphosphate, which provides faster, greater, and more consistent P2Y12 inhibition than Clopidogrel in patients with acute coronary syndrome, irrespective of the genetic variants affecting Clopidogrel metabolism. It is still undefined whether combination therapy of...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 11 December 2017.

1 Aug 2015 19 Jul 2015 10 Jun 2017 10 Mar 2018 1 Dec 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Single Blind (Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Efficacy Study
  • Intervention: Parallel Assignment

Contacts